Top Clinical Trials companies in Japan by EBITDA Margin
Japan
# |
Name |
EBITDA Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
55.70%
|
Dec. 31, 2023 | USD 21.58 | 0.31% |
|
Japan |
|
| 2 |
50.06%
|
March 31, 2024 | USD 14.75 | -0.46% |
|
Japan |
|
| 3 |
42.80%
|
Dec. 31, 2023 | USD 43.39 | 5.16% |
|
Japan |
|
| 4 |
33.95%
|
March 31, 2024 | USD 10.95 | -0.53% |
|
Japan |
|
| 5 |
32.20%
|
Dec. 31, 2023 | USD 13.83 | -0.63% |
|
Japan |
|
| 6 |
26.80%
|
Dec. 31, 2023 | USD 14.95 | -1.71% |
|
Japan |
|
| 7 |
26.34%
|
Sept. 30, 2024 | USD 9.46 | -2.05% |
|
Japan |
|
| 8 |
24.77%
|
March 31, 2024 | USD 25.51 | -0.96% |
|
Japan |
|
| 9 |
24.56%
|
March 31, 2024 | USD 3.56 | -3.55% |
|
Japan |
|
| 10 |
20.51%
|
March 31, 2024 | USD 27.12 | 0.10% |
|
Japan |
|
| 11 |
18.70%
|
March 31, 2024 | USD 10.09 | 0.15% |
|
Japan |
|
| 12 |
18.49%
|
March 31, 2024 | USD 17.95 | -0.66% |
|
Japan |
|
| 13 |
16.48%
|
June 30, 2024 | USD 8.09 | -0.35% |
|
Japan |
|
| 14 |
12.18%
|
March 31, 2024 | USD 9.76 | -1.53% |
|
Japan |
|
| 15 |
11.58%
|
March 31, 2024 | USD 11.15 | -1.27% |
|
Japan |
|
| 16 |
9.74%
|
March 31, 2024 | USD 2.22 | 6.19% |
|
Japan |
|
| 17 |
9.52%
|
March 31, 2024 | USD 9.48 | -0.72% |
|
Japan |
|
| 18 |
8.28%
|
March 31, 2024 | USD 15.32 | -0.42% |
|
Japan |
|
| 19 |
7.89%
|
March 31, 2024 | USD 9.47 | -2.44% |
|
Japan |
|
| 20 |
5.13%
|
March 31, 2024 | USD 2.10 | -1.79% |
|
Japan |
|
| 21 |
0.34%
|
March 31, 2024 | USD 0.72 | 0.32% |
|
Japan |
|
| 22 |
-5.88%
|
Dec. 31, 2023 | USD 2.56 | -2.54% |
|
Japan |
|
| 23 |
-11.31%
|
June 30, 2024 | USD 1.03 | -3.60% |
|
Japan |
|
| 24 |
-12.77%
|
Dec. 31, 2023 | USD 1.21 | 1.57% |
|
Japan |
|
| 25 |
-38.65%
|
March 31, 2024 | USD 5.69 | -0.47% |
|
Japan |
|
| 26 |
-44.70%
|
Dec. 31, 2023 | USD 6.24 | -4.05% |
|
Japan |
|
| 27 |
-67.15%
|
Dec. 31, 2023 | USD 1.90 | -2.24% |
|
Japan |
|
| 28 |
-102.92%
|
Dec. 31, 2023 | USD 0.24 | -0.59% |
|
Japan |
|
| 29 |
-210.70%
|
March 31, 2024 | USD 0.17 | -10.87% |
|
Japan |
|
| 30 |
-636.86%
|
March 31, 2024 | USD 0.90 | -0.59% |
|
Japan |
|
| 31 |
-3,061.16%
|
Dec. 31, 2023 | USD 3.68 | -3.46% |
|
Japan |
Frequently Asked Questions
-
Which Clinical Trials company in Japan has the highest EBITDA Margin ?
The Clinical Trials company in Japan with the highest EBITDA Margin is GNI Group Ltd. (Tokyo Stock Exchange: 2160.T) at 55.70%.
-
Which Clinical Trials company in Japan has the lowest EBITDA Margin ?
The Clinical Trials company in Japan with the lowest EBITDA Margin is Oncolys BioPharma Inc. (Tokyo Stock Exchange: 4588.T) at -3,061.16%.
-
What are the top 10 Clinical Trials companies in Japan by EBITDA Margin ?
The top 10 Clinical Trials companies in Japan by EBITDA Margin are GNI Group Ltd., Shionogi & Co., Ltd., Chugai Pharmaceutical Co., Ltd., Shin Nippon Biomedical Laboratories, Ltd., PeptiDream Inc., Kyowa Kirin Co., Ltd., Fuji Pharma Co., Ltd., Kissei Pharmaceutical Co., Ltd., JCR Pharmaceuticals Co., Ltd. and Takeda Pharmaceutical Company Limited.
-
What are the bottom 10 Clinical Trials companies in Japan by EBITDA Margin ?
The bottom 10 Clinical Trials companies in Japan by EBITDA Margin are Oncolys BioPharma Inc., NanoCarrier Co., Ltd., OncoTherapy Science, Inc., Solasia Pharma K.K., Carna Biosciences, Inc., Nxera Pharma Co., Ltd., Cytori Cell Research Institute, Inc., SymBio Pharmaceuticals Limited, Soiken Holdings Inc. and RaQualia Pharma Inc..
